RXST Stock Analysis: Rxsight | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 225m USD | 12M Return: -45.2% | US78349D1072 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.77M
Qual. Beats: 0
Rev. Trend: 62.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RxSight, Inc. (NASDAQ: RXST) is a U.S.-based, commercial-stage medical technology company that develops, manufactures, and sells the RxSight System, which is used in cataract surgery. The system consists of two main components: the Light Adjustable Lens (LAL), a photosensitive intraocular lens implanted in the eye, and a light delivery device that emits targeted UV light to non-invasively reshape the lens after surgery, allowing ophthalmologists to fine-tune the patients visual acuity post-procedure.
The company follows a hybrid business model, selling capital equipment (the light delivery device) to ophthalmologists while generating recurring revenue from the sale of the adjustable lenses as single-use consumables per procedure. Cataract surgery is one of the most frequently performed surgical procedures in the world, and the premium intraocular lens segment that RxSight targets represents a differentiated, higher-margin niche within the broader ophthalmology market. Headquartered in Aliso Viejo, California, the company was originally incorporated in 1997 as Calhoun Vision before adopting the RxSight name in February 2017. It trades on NASDAQ as a micro-cap stock following its July 2021 IPO.
- LAL procedure volume growth drives quarterly revenue beat
- Gross margin expansion accelerates path to profitability
- Competition from premium intraocular lens makers intensifies
| Net Income: -46.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.08 > 0.02 and ΔFCF/TA -0.97 > 1.0 |
| NWC/Revenue: 193.6% < 20% (prev 167.7%; Δ 25.90% < -1%) |
| CFO/TA -0.06 > 3% & CFO -22.7m > Net Income -46.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (41.5m) vs 12m ago 1.83% < -2% |
| Gross Margin: 77.50% > 18% (prev 68.42%; Δ 9.08% > 0.5%) |
| Asset Turnover: 38.56% > 50% (prev 50.86%; Δ -12.30% > 0%) |
| Interest Coverage Ratio: -3.12k > 6 (EBIT TTM -46.8m / Interest Expense TTM 15.0k) |
| A: 0.70 (Total Current Assets 327.4m - Total Current Liabilities 80.4m) / Total Assets 352.7m |
| B: -1.95 (Retained Earnings -689.0m / Total Assets 352.7m) |
| C: -0.14 (EBIT TTM -46.8m / Avg Total Assets 330.9m) |
| D: 2.95 (Book Value of Equity 263.3m / Total Liabilities 89.4m) |
| Altman-Z'' = 0.37 = B |
| DSRI: 3.0 (Receivables 78.5m/28.1m, Revenue 127.6m/157.2m) |
| GMI: 0.88 (GM 68.42% / 77.50%) |
| AQI: 1.20 (AQ_t 0.01 / AQ_t-1 0.00) |
| SGI: 0.81 (Revenue 127.6m / 157.2m) |
| TATA: -0.07 (NI -46.9m - CFO -22.7m) / TA 352.7m) |
| Beneish M = -1.51 (Cap -4..+1) = CCC |
As of September 21, 2026, the stock is trading at USD 5.20 with a total of 1,077,970 shares traded. Over the past week, the price has changed by -13.62%, over one month by -18.37%, over three months by +9.94% and over the past year by -45.21%.
Current recommended Stop Loss: 4.40 (which is 15.4% or 2.1 ATR below the current price).
Rxsight has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold RXST.
- StrongBuy: 4
- Buy: 2
- Hold: 3
- Sell: 2
- StrongSell: 0
| Analysts Target Price | 7.8 | 49.8% |
P/E Forward = 116.2791
P/S = 1.7605
P/B = 0.8861
Revenue TTM = 127.6m USD
EBIT TTM = -46.8m USD
EBITDA TTM = -43.3m USD
Long Term Debt = 8.92m USD (estimated: total debt 10.6m - short term 1.66m)
Short Term Debt = 1.66m USD (from shortTermDebt, last quarter)
Debt = 10.6m USD (from shortLongTermDebtTotal, last quarter) (leases 10.6m already included)
Net Debt = -198.2m USD (calculated: Debt 10.6m - CCE 208.8m)
Enterprise Value = 26.4m USD (224.6m + Debt 10.6m - CCE 208.8m)
Interest Coverage Ratio = -3.12k (Ebit TTM -46.8m / Interest Expense TTM 15.0k)
EV/FCF = -0.97x (Enterprise Value 26.4m / FCF TTM -27.2m)
FCF Yield = -103.0% (FCF TTM -27.2m / Enterprise Value 26.4m)
FCF Margin = -21.29% (FCF TTM -27.2m / Revenue TTM 127.6m)
Net Margin = -36.80% (Net Income TTM -46.9m / Revenue TTM 127.6m)
Gross Margin = 77.50% ((Revenue TTM 127.6m - Cost of Revenue TTM 28.7m) / Revenue TTM)
Gross Margin QoQ = 76.72% (prev 76.06%)
Tobins Q-Ratio = 0.07 (Enterprise Value 26.4m / Total Assets 352.7m)
Interest Expense / Debt = 0.14% (Interest Expense 15.0k / Debt 10.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -37.0m (EBIT -46.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.07 (Total Current Assets 327.4m / Total Current Liabilities 80.4m)
Debt / Equity = 0.04 (Debt 10.6m / totalStockholderEquity, last quarter 263.3m)
Debt / EBITDA = 4.58 (negative EBITDA) (Net Debt -198.2m / EBITDA -43.3m)
Debt / FCF = 7.30 (negative FCF - burning cash) (Net Debt -198.2m / FCF TTM -27.2m)
Total Stockholder Equity = 270.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.19% (Net Income -46.9m / Total Assets 352.7m)
RoE = -17.35% (Net Income TTM -46.9m / Total Stockholder Equity 270.6m)
RoCE = -16.75% (EBIT -46.8m / Capital Employed (Equity 270.6m + L.T.Debt 8.92m))
RoIC = -13.83% (negative operating profit) (NOPAT -37.0m / Invested Capital 267.5m)
WACC = 8.15% (E(224.6m)/V(235.2m) * Re(8.53%) + D(10.6m)/V(235.2m) * Rd(0.14%) * (1-Tc(0.21)))
Discount Rate = 8.53% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 88.66 | Cagr: 5.42%
[DCF] Fair Price = unknown (Cash Flow -27.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.58 | # QB: 0
Revenue Correlation: 62.52 | Revenue CAGR: 14.10% | SUE: 0.34 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.15 | Chg30d=+8.48% | Revisions=-29% | Analysts=5
EPS current Year (2026-12-31): EPS=-0.27 | Chg30d=+60.76% | Revisions=+57% | GrowthEPS=-52.6% | GrowthRev=+9.5%
EPS next Year (2027-12-31): EPS=-0.70 | Chg30d=-24.46% | Revisions=+0% | GrowthEPS=-153.7% | GrowthRev=+1.4%
[Analyst] Revisions Ratio: +13% (up=7, down=5)